Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial - Subbiah, Vivek; Wolf, Jürgen; Konda, Bhavana; Kang, Hyunseok; Spira, Alexander; Weiss, Jared; Takeda, Masayuki; Ohe, Yuichiro; Khan, Saad; Ohashi, Kadoaki; Soldatenkova, Victoria; Szymczak, Sylwia; et al. (The lancet oncology, 2022)
Keywords: Adverse events; Alanine; Alanine Transaminase; Aspartate aminotransferase; Aspartate Aminotransferases; Biomarkers; Carcinoma, Non-Small-Cell Lung - drug therapy; Disease; Drug dosages; Enzyme inhibitors; FDA approval; Health facilities; Hematology, Oncology, and Palliative Medicine; Humans; Laboratories; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical research; Non-small cell lung carcinoma; Oncology; Oral administration; Patients; Population; Protein Kinase Inhibitors - adverse effects; Proto-Oncogene Proteins c-ret - genetics; Pyrazoles; Pyridines; Regulatory approval; Response rates; Safety; Solid tumors; Thyroid cancer; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - genetics; Tumors; United States--US